[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"magnetic-resonance-spectroscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:magnetic-resonance-spectroscopy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,75,115,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100476982","mri-biomarkers-predictive-of-disability-progression-in-patients-with-multiple-sclerosis-100476982",false,"NCT05491031","MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis","Evaluation of MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis","Inclusion Criteria:\n\n* Age ≥ 18 years,\n* Duration of disease ≤ 25 years,\n* Irreversible disability ≤ 7 (permanent wheelchair use) on the EDSS scale\n\nExclusion Criteria:\n\n* Other progressive neurological disease,\n* Isolated radiologic syndrome (RIS),\n* Severe psychiatric pathology not in balance,\n* Change in dosage, discontinuation or initiation of a psychotropic treatment within the last month,\n* Change in background MS treatment for less than 3 months,\n* A course of corticosteroids (oral or intravenous) for less than one month,\n* Patient with a contraindication to MRI: pregnancy, metallic ocular foreign body (accidental splinters or others), pacemaker, implantable defibrillator, neurostimulator not compatible with MRI 7.0 T, cochlear implants and in general any electronic medical equipment implanted in an irremovable way: metallic cardiac valve, vascular clips (formerly implanted on cranial aneurysm), metallic prosthesis...),\n* Illiterate and non-French speaking patient: patient who is partially or completely unable to read and write French.\n* Patient benefiting from reinforced protection, i.e. minor, subject deprived of liberty by a judicial or administrative decision, subject staying in a health or social establishment, adult under legal protection and finally patient in emergency situation,\n* Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal\u002Fmechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","The transition from relapsing-remitting multiple sclerosis to secondarily progressive multiple sclerosis (SPMS) is difficult to identify. Typically, SPMS is diagnosed retrospectively, with a significant delay, on the basis of a clinical history of progressive worsening, independent of relapses. Thus, SPMS is often associated with a considerable period of diagnostic uncertainty.\n\nThe use of ultra-high field imaging can shed light on the mechanisms of disability progression thanks to its better spatial resolution and advanced imaging techniques.\n\nThe new morphological imaging techniques make it possible to visualize chronic inflammatory lesions and to evaluate their evolution. It also allows for the precise measurement of brain atrophy, a reference in the evaluation of neurodegeneration.\n\nMetabolic imaging via proton spectroscopy allows the analysis of several promising cerebral metabolites that can provide information on cellular energy metabolism, mitochondrial function, or oxidative stress, and can help identify tissues at risk of neurodegeneration. Sodium imaging can provide information on axonal energy metabolism before the occurrence of stable and irreversible axonal damage. This technique is promising as an early marker of neurodegeneration.",[26,27],"Multiple Sclerosis","Magnetic Resonance Spectroscopy",[29,30,31,32],"Multiple sclerosis","ultra-high field 7T magnetic resonance spectroscopy","sodium imaging","predictive MR biomarker of MS","RECRUITING","2026-05-04",{"date":36,"type":37},"2026-05-05","ACTUAL",{"date":39,"type":37},"2023-04-25",{"date":41,"type":20},"2030-05-01",{"name":43,"class":44},"Poitiers University Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100451979","non-invasive-monitoring-of-metabolite-levels-using-novel-and-adapted-mr-spectroscopy-techniques-100451979","NCT05165537","Non-Invasive Monitoring Of Metabolite Levels Using Novel And Adapted MR Spectroscopy Techniques","Evaluation of Novel and Adapted MR Spectroscopy and Metabolic Imaging Techniques for Non-invasive Monitoring of Metabolite Levels in Humans in Physiologic States of Everyday Life","NIMM_MRS","Inclusion Criteria:\n\n* signed informed consent\n* healthy (no neuronal or metabolic diseases as stated by the study participant)\n* able to lie still in the MR scanner for at least one hour\n\nExclusion Criteria:\n\n* \\\u003C18 yrs of age\n* pregnancy or current state of lactation\n* active implants\n* passive ferromagnetic implants\n* passive non-ferromagnetic metallic implants \\> 4 cm inside a region covered by the active radio-frequency (RF) coils\n* large tattoos inside a region covered by the active RF coils\n* known or suspected non-compliance,\n* under-weight (\\\u003C35 kg body weight)",true,{"count":56,"type":20},100,[23],"This Swiss National Science Foundation (SNF) funded project and the linked European project aim\n\n* to improve magnetic resonance (MR) methods, specifically MR spectroscopy and metabolic imaging (making them more sensitive and accurate - also less dependent on motion),\n* to extend them (making previously unobservable metabolites visible) and also\n* to make them more stable (suitable for routine clinical use).\n\nMagnetic resonance spectroscopy (MRS) is closely related to the widely used magnetic resonance imaging (MRI). Both methods are based on the same physical effect and are performed on the same equipment. However, while MRI mainly images the anatomy inside the body, MRS gives us information about the metabolism of the tissue. The main goal of this study is to develop and improve methods of MRS to better measure the concentrations of endogenous substances without actual intervention. MRS methodology development is performed in 4 steps:\n\n1. A new method is developed and optimized theoretically and in sample preparations (solutions of chemicals).\n2. The new methodology is evaluated in single healthy volunteers and optimized step by step for the conditions of use in the human body.\n3. The methodology in evaluated in small groups of healthy volunteers (measurement accuracy and range of variation in healthy volunteers).\n4. Feasibility is studied in different situations with possibly different metabolic situations (e.g. awake versus asleep or before and after muscular exertion).\n\nFor this purpose, about 100 subjects will be measured for different subprojects. Thus, among other things, one determines the measurement accuracy and also normal values in healthy subjects for the assessment of diseases in future studies.",[27],[61,62,63,64,65],"brain","muscle","healthy subjects","precision","repeatability","2026-04-28",{"date":68,"type":37},"2026-04-29",{"date":70,"type":37},"2022-03-01",{"date":72,"type":20},"2028-12",{"name":74,"class":44},"Insel Gruppe AG, University Hospital Bern",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":54,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":45},"100635242","etascan-project-etas-project-2-100635242","NCT07550140","ETASCAN Project: ETAS Project 2","The Impact of Chronic Consumption of ETAS® for 12 Weeks on Cognitive, Affective, and Neural Outcomes: A Randomised Parallel Group Placebo-controlled Study","ETASCAN","Inclusion Criteria:\n\n* Aging between 60-80 years old\n* Having normal vision and hearing\n* Having a body mass index between 18.5 and 30\n* Having mild to moderate subjective cognitive complaints\n\nExclusion Criteria:\n\n* Smoking\n* Having food allergies\n* Following restrictive and\u002For unbalanced diets (Appendix 6: Are you vegetarian or vegan? Yes \u002F No; Are you currently on a weight-reducing or other special diet? Yes\u002FNo If 'Yes', please give details.)\n* Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders\n* Being diagnosed with any cardiometabolic diseases (including type II diabetes and cardiovascular disease), or hypertension or thrombosis related disorders or suffer from thyroid disease\n* Currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors\n* Currently consuming prebiotic or probiotic supplements\n* Continuous antibiotic use for \\> 3 days within 1 month prior to enrolment\n* Continuous use of weight-loss drug for \\> 1 month before screening\n* Having a significant gastrointestinal (GI) condition affecting absorption including (but not limited to) inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years\n* History of claustrophobia\n* Fitted with a pacemaker or artificial heart valve\n* Have active implants, such as cochlear, ocular, or penile implant\n* Experience of metal fragments e.g. shrapnel in your eyes or any other part of your body\n* Drug infusion pump installed\n* Have any surgically implanted metal in any part of your body, other than dental fillings and crowns (e.g. joint replacement or bone re-construction)\n* Have had any surgery that might have involved metal implants\n* Current or historical experience of epilepsy\n* Have stimulators for nerves, brain or bone installed\n* Have an intrauterine contraceptive device installed (IUD)\n* Wear transdermal patches containing metal\n* Wear a filling, crown, dental post (entirely within the tooth) associated with root canal treatment, retainer, bridge or braces\n* For scanning, would need to remove coloured contact lenses, nail polish and makeup.\n* Hearing aid wearer\n* Body piercings that you cannot or will not remove for the scanning session\n* Have tattoos or permanent makeup","60 Years","80 Years",{"count":86,"type":20},60,[23],"This study aims to investigate the chronic effects of ETAS® on cognitive, affective and neural outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.",[90,91,92,93,94,27],"Cognition","Affect (Mental Function)","Sleep","MRI","fMRI",[96,97,98,99,100,101,102,103,104,105,106],"grey matter","brain structure","brain function","neurochemistry","executive function","language","ETAS®","depression","anxiety","sleep","gut microbiome","2026-04-17",{"date":109,"type":37},"2026-04-24",{"date":36,"type":20},{"date":112,"type":20},"2027-12-31",{"name":114,"class":44},"University of Reading",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":45},"100545023","effects-of-tdcs-for-enhancing-cognitive-function-in-individuals-with-persistent-post-concussion-syndrome-100545023","NCT06376500","Effects of tDCS for Enhancing Cognitive Function in Individuals With Persistent Post-Concussion Syndrome","Effects of Transcranial Direct Current Stimulation for Enhancing Cognitive Function in Individuals With Persistent Post-Concussion Syndrome: A Pilot fMRI\u002F1H-MRS Study","Inclusion Criteria:\n\n* being 18 years old or older;\n* having a history of a mild TBI (less than 30 minutes loss of consciousness) 1-6 years prior to the study;\n* able to communicate in Chinese.\n\nExclusion Criteria:\n\n* being without a confirmed diagnosis from the medical practitioner;\n* having a history of other neurological and psychiatric disorders, skull defect, recent medical instability (within 3 weeks);\n* being pregnant;\n* being medication for a psychiatric condition (e.g., major depression, anxiety, schizophrenia);\n* with any implanted devices or suffering from real claustrophobia or feel uncomfortable in small, enclosed spaces, like MRI tunnel","65 Years",{"count":124,"type":20},40,[23],"Globally, 10 million new traumatic brain injury (TBI) cases are estimated annually, with mild traumatic brain injury (mTBI) accounting for 75-90% of all TBI cases. It is estimated that 40-80% of individuals with mTBI may experience the post-concussion syndrome (PCS), which is characterized by a range of physical, cognitive, and emotional symptoms. Although the underlying basis of cognitive dysfunction of patients with persistent PCS remains to be clarified, converging evidence shows that the clinical symptoms is underpinned by abnormal neural information processing as a result of axonal injury due to mTBI. Recent studies have demonstrated abnormalities in both structural and functional cortical connectivity, and a loss of cortical excitability-inhibitory (E\u002FI) balance after TBI. Yet, there is no consensus for treating chronic symptoms of concussion, and PCS remains a chronic and highly disabling condition. One potential treatment option is transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique that has been shown to modify behavior by enhancing connectivity between targeted brain areas. However, research on the therapeutic effect of tDCS on PCS symptoms is limited, and the neurologic mechanisms underlying its effects are not well understood. The proposed study aims to address these knowledge gaps by examining the effects of tDCS on the central nervous system function in patients with PCS, with a specific focus on functional cortical connectivity and cognitive functions such as processing speed and executive function. The study also aims to add value to existing evidence by potentially opening new directions for designing intervention programs for the treatment of PCS after mTBI.",[128,129,130,27],"Transcranial Direct Current Stimulation","Post-Concussion Syndrome","Functional Magnetic Resonance Imaging","2025-09-18",{"date":133,"type":37},"2025-09-19",{"date":135,"type":37},"2025-09-01",{"date":137,"type":20},"2028-02",{"name":139,"class":44},"The Hong Kong Polytechnic University",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":45},"100511432","new-imaging-biomarkers-predictive-of-ma-progression-100511432","NCT05939362","New Imaging Biomarkers Predictive of MA Progression","Identifying Imaging Biomarkers Predictive of Disability Progression in Alzheimer's Disease: Pilot Study","MR7T-PRADA","Inclusion Criteria:\n\n* French-speaking patients aged 60 to 90 years,\n* Patient in the context of Alzheimer's disease \\* for which imaging after MRI is prescribed as part of the usual diagnostic process,\n\n  \\*Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR\u002FRI defined by a sum of LR \\\u003C 17\u002F48 and sum of RT \\\u003C 40\u002F48 +\u002F- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +\u002F- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery).\n* MMSE score ≥18,\n* Written informed consent after the patient has been informed,\n* Progressive decline for at least 6 months.\n\nExclusion Criteria:\n\n--Partially or completely illiterate patient unable to read and write,\n\n* Patient with an absolute contraindication to 7T MRI\n* Severe psychiatric pathology not balanced,\n* Non-degenerative neurological disease (stroke, multiple sclerosis ...),\n* Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score \\> 3)","90 Years",{"count":150,"type":20},80,[23],"The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death.\n\nUltra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.",[154,27,155,156,157],"Alzheimer Disease","Ultra High Field 7T","Progression of Disease","MR Biomarkers","2024-12-05",{"date":160,"type":37},"2024-12-10",{"date":162,"type":37},"2023-10-02",{"date":164,"type":20},"2028-01-15",{"name":43,"class":44}]